Slide Show: Prostate Cancer

Slideshow

This slide show features pathology slides and PET/CT scans of prostate cancer, as well as various images of bone lesions from metastatic disease.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content
A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.

FDA Selects Detalimogene for Manufacturing Pilot Program in NMIBC

Roman Fabbricatore
December 3rd 2025
Article

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Site Logo

BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer

Roman Fabbricatore
November 1st 2025
Article

Among patients with locally advanced/metastatic urothelial cancer who received at least one 2.2 mg/kg dose of BL-B01D1, the confirmed ORR was 44.1%.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Regarding safety, the toxicity profile of the pembrolizumab plus belzutifan combination was consistent with what has been observed in previously reported trials.

Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy

Tim Cortese
October 29th 2025
Article

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.

The developers will present these data at an upcoming medical meeting and plan to begin discussions with regulatory authorities.

Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC

Tim Cortese
October 28th 2025
Article

Belzutifan/lenvatinib also showed a favorable trend toward improvement for overall survival in this advanced renal cell carcinoma population.